Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic.
about
Risperidone (depot) for schizophreniaAntipsychotic medication for early episode schizophreniaRisperidone versus placebo for schizophreniaDepot risperidone for schizophreniaPublication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration databaseClinical utility of the risperidone formulations in the management of schizophrenia.In vitro and in vivo demonstration of risperidone implants in mice.NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery.Effectiveness of switching from antipsychotic polypharmacy to monotherapy.Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial.Resource utilization in patients with schizophrenia who initiated risperidone long-acting therapy: results from the Schizophrenia Outcomes Utilization Relapse and Clinical Evaluation (SOURCE).A composite approach that includes dropout rates when analyzing efficacy data in clinical trials of antipsychotic medicationsThe association of dropout and outcome in trials of antipsychotic medication and its implications for dealing with missing data.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia.The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statementsEfficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews.Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium.Long-acting risperidone: a review of its role in the treatment of bipolar disorder.Psychotic disorders in children and adolescents: a primer on contemporary evaluation and managementWhere schizophrenic patients commit suicide: a review of suicide among inpatients and former inpatients.Assessment of effectiveness measures in patients with schizophrenia initiated on risperidone long-acting therapy: the SOURCE study resultsLong acting risperidone in Australian patients with chronic schizophrenia: 24-month data from the e-STAR databaseWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects.Extended release drug delivery strategies in psychiatry: theory to practiceThe role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.Placebo response in antipsychotic clinical trials: a meta-analysis.A Prospective Study Comparing the Long-term Effectiveness of Injectable Risperidone Long-acting Therapy and Oral Aripiprazole in Patients with SchizophreniaClinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America.Interrelations between psychiatric symptoms and drug-induced movement disorder.Risperidone long-acting injection in Schizophrenia Spectrum Illnesses compared to first generation depot antipsychotics in an outpatient setting in Canada.Adverse effects associated with second-generation antipsychotic long-acting injection treatment: a comprehensive systematic review.Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trialPharmacological enhancement of naltrexone treatment for opioid dependence: a reviewDeltoid injections of risperidone long-acting injectable in patients with schizophreniaLong-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia.Poor response to treatment: beyond medication.Efficacy and safety of flexibly dosed paliperidone palmitate in Chinese patients with acute schizophrenia: an open-label, single-arm, prospective, interventional study.Five-year patient outcomes with risperidone long-acting injection or oral aripiprazole.The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning.Long-acting injectable risperidone.
P2860
Q24185901-677B83C9-3FED-4D30-BF8C-5C52878120EAQ24236683-FD3D46C1-3A56-43F3-B036-C9D36F635A8DQ24241041-9FF4C676-86F2-4AA1-A9B4-FC0FF215D4A6Q24247787-ECCC8F23-846A-47FD-86F5-81271836850FQ28481584-EA127365-E9F9-486C-AF3D-5BE56E006998Q30429721-BA858186-13A6-4A46-BA2F-708D2ED2DE9AQ30493152-E4E260AF-D68C-4E20-B726-367F66168609Q30493643-61D63A79-F6AC-4FBD-86A8-A334117686BCQ30542484-437689B4-231B-4508-9743-93C7434CA29CQ30542486-7F02845D-781B-43CD-A065-E276EDB394E3Q31038656-B5711ECD-F234-458E-8780-9A5FD56A8084Q31131634-DD16A467-A549-4C96-81DF-0A5884917BA1Q31143463-CB3899C8-122F-44D5-87B5-A05A5439B673Q33235110-15FDC66A-6DAE-440D-9635-39721FA634D2Q33566124-753E788C-88FD-48B3-818F-C957518F2862Q33724292-119CEDC9-4D07-4539-B0CB-52B0FDF8EA86Q33862078-35EEC2AB-5462-4D94-9C32-87D70483B170Q33886093-3AE3C5A8-1988-4D79-A03E-62DB2F3C0835Q33975802-03F4722B-905D-48F6-B848-22991F62650DQ33990881-21624F10-91C0-481F-B81B-5D9845F5F081Q34048194-D4C5F6FD-E088-41C6-A818-96EB299535FDQ34208127-44E1AC55-4670-4FA5-BA1A-2C3DCA54BD03Q34315836-34F420C9-82C1-405F-92F4-5ADC3DA7077DQ34396625-0FE673D2-99F7-42BC-875E-C7B93B9E24B7Q34418847-1ABCAC05-1009-4D60-B059-2C93D5D8DDF4Q34443837-8D0095DD-DC66-4432-9F63-CEF65EA7DD5DQ34444162-0F484538-6113-4A7D-829F-D0FB42F76932Q34560335-CB2D9263-2497-4959-970F-E82AEB241BDEQ34573844-E8DACCE3-9671-42DE-970A-B9F7F4DE2328Q34746791-73058458-6D8F-4494-8008-2BBAC415AC0EQ34775426-1034677F-D39A-4D1E-BE87-2BFD3AF621C9Q34855041-6D2A17EB-3857-47A2-9C52-9730FA726087Q35084340-5B184AAB-4089-4842-A271-F00F4CFA9283Q35119881-E5DBFC43-5FCB-470F-85B0-F646691886CDQ35143555-6007C59B-0BD2-4346-B6E8-8605D32E028FQ35236765-6F724CBF-CA02-40AD-9097-9C8CC1E2CAE7Q35794615-09B54F39-3B45-4905-BC14-D9F5B9B481AAQ35852541-07BA59C4-C40D-4965-9A15-B7543A242855Q35930948-A5003A88-BB66-492A-B7B3-FC000979EDFEQ35937703-D85AFD88-6B59-47B2-8015-05DCE48B6179
P2860
Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Long-acting injectable risperi ...... acting atypical antipsychotic.
@en
Long-acting injectable risperi ...... acting atypical antipsychotic.
@nl
type
label
Long-acting injectable risperi ...... acting atypical antipsychotic.
@en
Long-acting injectable risperi ...... acting atypical antipsychotic.
@nl
prefLabel
Long-acting injectable risperi ...... acting atypical antipsychotic.
@en
Long-acting injectable risperi ...... acting atypical antipsychotic.
@nl
P2093
P1476
Long-acting injectable risperi ...... acting atypical antipsychotic.
@en
P2093
Jean-Pierre Lindenmayer
Keith Karcher
Mariëlle Eerdekens
Michael Lesem
Samuel J Keith
P304
P356
10.1176/APPI.AJP.160.6.1125
P407
P50
P577
2003-06-01T00:00:00Z